FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913178269> ?p ?o ?g. }

• W2913178269 abstract "Chronic active Epstein-Barr virus infection (CAEBV) is one of the Epstein-Barr virus (EBV)-positive T- or NK-lymphoproliferative diseases. It has been considered rare and geographically limited to Japan and East Asia. However, CAEBV is drawing international attention, and the number of case reports is increasing worldwide after its classification into EBV-positive T- or NK-cell neoplasms in the 2016 WHO classification. In this article, I review current advances in the study of CAEBV under the new definition and show future directions. In CAEBV, EBV-infected T or NK cells clonally proliferate and infiltrate multiple organs, leading to their failure. These characteristics define CAEBV as a lymphoid neoplasm. However, the main symptom of CAEBV is inflammation. Recently, the mechanisms underlying the development of CAEBV have gradually become clearer. EBV infection of T or NK cells can occur during the acute phase of primary infection with a high EBV load in the peripheral blood. In addition, it was reported that cytotoxic T cells were decreased in number or showed dysfunction in CAEBV. These findings suggest that undetermined immunosuppressive disorders may underlie persistent infection of T or NK cells. Furthermore, EBV itself contributes to the survival of host cells. In vitro EBV infection of T cells induced intercellular survival-promoting pathways. Constitutive activation of NF-kB and STAT3 was observed in EBV-positive T or NK cells in CAEBV, promoting not only cell survival but also CAEBV development. During the disease course, CAEBV can lead to 2 lethal conditions: hemophagocytic lymphohistiocytosis and chemotherapy-resistant lymphoma. It is necessary to start treatment before these conditions develop. At present, the only effective treatment strategy for eradicating EBV-infected T or NK cells is allogeneic stem cell transplantation (allo-HSCT). However, patients with active disease, in which the condition is accompanied by fever, liver dysfunction, progressive skin lesions, vasculitis, or uveitis, had worse outcomes after allo-HSCT than did patients with inactive disease. Unfortunately, current chemotherapies are insufficient to improve the activity of CAEBV. Based on the molecular mechanisms for the development of the disease, the NF-kB or JAK/STAT mediating pathways are attractive candidate targets for new treatments." @default.
• W2913178269 created "2019-02-21" @default.
• W2913178269 creator A5086342547 @default.
• W2913178269 date "2019-02-05" @default.
• W2913178269 modified "2023-10-03" @default.
• W2913178269 title "Advances in the Study of Chronic Active Epstein-Barr Virus Infection: Clinical Features Under the 2016 WHO Classification and Mechanisms of Development" @default.
• W2913178269 cites W1494539247 @default.
• W2913178269 cites W1495420648 @default.
• W2913178269 cites W1505046337 @default.
• W2913178269 cites W1513728646 @default.
• W2913178269 cites W1972115977 @default.
• W2913178269 cites W1974696705 @default.
• W2913178269 cites W1975615991 @default.
• W2913178269 cites W1985199344 @default.
• W2913178269 cites W1987240796 @default.
• W2913178269 cites W1995081407 @default.
• W2913178269 cites W2027479009 @default.
• W2913178269 cites W2031423829 @default.
• W2913178269 cites W2033107164 @default.
• W2913178269 cites W2040626805 @default.
• W2913178269 cites W2041531470 @default.
• W2913178269 cites W2041763575 @default.
• W2913178269 cites W2045994384 @default.
• W2913178269 cites W2052425622 @default.
• W2913178269 cites W2054300739 @default.
• W2913178269 cites W2054341505 @default.
• W2913178269 cites W2073631928 @default.
• W2913178269 cites W2083278363 @default.
• W2913178269 cites W2093709330 @default.
• W2913178269 cites W2093724620 @default.
• W2913178269 cites W2094342081 @default.
• W2913178269 cites W2095572685 @default.
• W2913178269 cites W2112302941 @default.
• W2913178269 cites W2118028844 @default.
• W2913178269 cites W2133694740 @default.
• W2913178269 cites W2136822841 @default.
• W2913178269 cites W2145714404 @default.
• W2913178269 cites W2149250436 @default.
• W2913178269 cites W2156374986 @default.
• W2913178269 cites W2165608602 @default.
• W2913178269 cites W2169924528 @default.
• W2913178269 cites W2171406432 @default.
• W2913178269 cites W2211802557 @default.
• W2913178269 cites W2279620479 @default.
• W2913178269 cites W2281266559 @default.
• W2913178269 cites W2299263630 @default.
• W2913178269 cites W2310716991 @default.
• W2913178269 cites W2327153404 @default.
• W2913178269 cites W2408907231 @default.
• W2913178269 cites W2581954986 @default.
• W2913178269 cites W2589130275 @default.
• W2913178269 cites W2600299536 @default.
• W2913178269 cites W2610090714 @default.
• W2913178269 cites W2736396926 @default.
• W2913178269 cites W2742681205 @default.
• W2913178269 cites W2775677382 @default.
• W2913178269 cites W2797236287 @default.
• W2913178269 cites W2800777307 @default.
• W2913178269 cites W2803975545 @default.
• W2913178269 cites W2884301740 @default.
• W2913178269 cites W2885074747 @default.
• W2913178269 cites W2891863700 @default.
• W2913178269 cites W2898779567 @default.
• W2913178269 cites W644234115 @default.
• W2913178269 cites W977201031 @default.
• W2913178269 doi "https://doi.org/10.3389/fped.2019.00014" @default.
• W2913178269 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6370717" @default.
• W2913178269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30805320" @default.
• W2913178269 hasPublicationYear "2019" @default.
• W2913178269 type Work @default.
• W2913178269 sameAs 2913178269 @default.
• W2913178269 citedByCount "60" @default.
• W2913178269 countsByYear W29131782692019 @default.
• W2913178269 countsByYear W29131782692020 @default.
• W2913178269 countsByYear W29131782692021 @default.
• W2913178269 countsByYear W29131782692022 @default.
• W2913178269 countsByYear W29131782692023 @default.
• W2913178269 crossrefType "journal-article" @default.
• W2913178269 hasAuthorship W2913178269A5086342547 @default.
• W2913178269 hasBestOaLocation W29131782691 @default.
• W2913178269 hasConcept C142724271 @default.
• W2913178269 hasConcept C154317977 @default.
• W2913178269 hasConcept C202751555 @default.
• W2913178269 hasConcept C203014093 @default.
• W2913178269 hasConcept C2522874641 @default.
• W2913178269 hasConcept C2779079688 @default.
• W2913178269 hasConcept C2779134260 @default.
• W2913178269 hasConcept C2779338263 @default.
• W2913178269 hasConcept C54355233 @default.
• W2913178269 hasConcept C71924100 @default.
• W2913178269 hasConcept C86803240 @default.
• W2913178269 hasConceptScore W2913178269C142724271 @default.
• W2913178269 hasConceptScore W2913178269C154317977 @default.
• W2913178269 hasConceptScore W2913178269C202751555 @default.
• W2913178269 hasConceptScore W2913178269C203014093 @default.
• W2913178269 hasConceptScore W2913178269C2522874641 @default.
• W2913178269 hasConceptScore W2913178269C2779079688 @default.
• W2913178269 hasConceptScore W2913178269C2779134260 @default.
• W2913178269 hasConceptScore W2913178269C2779338263 @default.
• W2913178269 hasConceptScore W2913178269C54355233 @default.

• next